“…miR-17 is the only validated miRNA whose expression has been shown to be directly regulated by IRE1-mediated cleavage ( 40 ), and has been shown to be involved in tumor aggressiveness in gliobastoma ( 145 ), hepatocellular carcinoma ( 146 ), and prostate ( 147 ), kidney ( 148 ), gastric ( 149 ), and colon ( 150 ) cancers. However, IRE1 has also been implicated in the degradation of other premiRNAs that are involved in cancer development, such as miR-96 , whose overexpression has been observed in bladder ( 151 ), prostate ( 152 ), and breast ( 153 ) cancers and has been shown to possess tumor-suppressor functions in pancreatic cancer ( 154 ). Overall, because RIDD targets are thought to depend on the cellular context (abundance of the respective substrates in a given cell type), the stimuli engaging IRE1 (nature of the UPRosome formed as well as size of the oligomers), and the presence of somatic mutations altering IRE1 conformation, we predict that this specifi c output of the UPR, together with the expression of classic ER stress transcription factors, will drive distinct gene-expression patterns that affect multiple aspects of cancer biology, including control of (i) the tumor cell death/survival balance, (ii) tumor cell invasion and metastasis properties, and (iii) the nature of the tumor stroma.…”